Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review.

Villas-Boas, CB; Chierrito, D; Fernandez-Llimos, F; Tonin, FS; Sanches, ACC

Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review.

Villas-Boas, CB Chierrito, D Fernandez-Llimos, F

Tonin, FS Sanches, ACC

Permalink

Publisher:: LIPPINCOTT WILLIAMS & WILKINS
Publication Type:: Journal Article
Citation:: International clinical psychopharmacology, 2019, 34, (2), pp. 57-64
Issue Date:: 2019-03

Closed Access

	Filename	Description	Size
	PAC-10036074.pdf	Published version	207.37 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Villas-Boas, CB
dc.contributor.author	Chierrito, D
dc.contributor.author	Fernandez-Llimos, F https://orcid.org/0000-0002-8529-9595
dc.contributor.author	Tonin, FS
dc.contributor.author	Sanches, ACC
dc.date.accessioned	2020-05-21T22:27:32Z
dc.date.available	2020-05-21T22:27:32Z
dc.date.issued	2019-03
dc.identifier.citation	International clinical psychopharmacology, 2019, 34, (2), pp. 57-64
dc.identifier.issn	0268-1315
dc.identifier.issn	1473-5857
dc.identifier.uri	http://hdl.handle.net/10453/140873
dc.description.abstract	The purpose of this study was to conduct a systematic review of the pharmacological options available to treat patients diagnosed with attention-deficit hyperactivity disorder and anxiety disorder, for generating evidence on the safest, most-effective and tolerable pharmacotherapy. To this end, a systematic search was performed in three electronic databases (Medline, Scopus and Directory of Open Access Journals; December 2017). Randomized, double-blind, parallel-design clinical trials evaluating the efficacy, safety or tolerability of therapies for attention-deficit hyperactivity disorder and anxiety disorder in children and adolescents or adults were considered. A total of 1960 articles were retrieved from the databases, of which five studies were included in the qualitative synthesis. Two of these studies evaluated the drug atomoxetine, another study evaluated desipramine, and the remaining two studies evaluated methylphenidate, with fluvoxamine being associated with methylphenidate in one of the trials. Owing to the high heterogeneity among studies, it was not possible to combine data for meta-analyses. Although only few studies have been evaluated in this systematic review, the results point to a more significant benefit of atomoxetine. This is probably because this drug was studied in a wider age range and evaluated by more specific scales for both disorders. To further strengthen this evidence, randomized, controlled and multicenter clinical trials with larger sample sizes should be conducted.
dc.format	Print
dc.language	eng
dc.publisher	LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof	International clinical psychopharmacology
dc.relation.isbasedon	10.1097/yic.0000000000000243
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences, 1701 Psychology
dc.subject.classification	Psychiatry
dc.subject.mesh	Humans
dc.subject.mesh	Fluvoxamine
dc.subject.mesh	Methylphenidate
dc.subject.mesh	Desipramine
dc.subject.mesh	Central Nervous System Agents
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Double-Blind Method
dc.subject.mesh	Anxiety Disorders
dc.subject.mesh	Attention Deficit Disorder with Hyperactivity
dc.subject.mesh	Comorbidity
dc.subject.mesh	Adolescent
dc.subject.mesh	Adult
dc.subject.mesh	Child
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Randomized Controlled Trials as Topic
dc.subject.mesh	Atomoxetine Hydrochloride
dc.subject.mesh	Adolescent
dc.subject.mesh	Adult
dc.subject.mesh	Anxiety Disorders
dc.subject.mesh	Atomoxetine Hydrochloride
dc.subject.mesh	Attention Deficit Disorder with Hyperactivity
dc.subject.mesh	Central Nervous System Agents
dc.subject.mesh	Child
dc.subject.mesh	Comorbidity
dc.subject.mesh	Desipramine
dc.subject.mesh	Double-Blind Method
dc.subject.mesh	Female
dc.subject.mesh	Fluvoxamine
dc.subject.mesh	Humans
dc.subject.mesh	Male
dc.subject.mesh	Methylphenidate
dc.subject.mesh	Randomized Controlled Trials as Topic
dc.subject.mesh	Treatment Outcome
dc.title	Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review.
dc.type	Journal Article
utslib.citation.volume	34
utslib.location.activity	England
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
utslib.for	1701 Psychology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
utslib.for	1701 Psychology
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	closed_access	*
dc.date.updated	2020-05-21T22:27:21Z
pubs.issue	2
pubs.publication-status	Published
pubs.volume	34
utslib.start-page	57
utslib.citation.issue	2

Abstract:

The purpose of this study was to conduct a systematic review of the pharmacological options available to treat patients diagnosed with attention-deficit hyperactivity disorder and anxiety disorder, for generating evidence on the safest, most-effective and tolerable pharmacotherapy. To this end, a systematic search was performed in three electronic databases (Medline, Scopus and Directory of Open Access Journals; December 2017). Randomized, double-blind, parallel-design clinical trials evaluating the efficacy, safety or tolerability of therapies for attention-deficit hyperactivity disorder and anxiety disorder in children and adolescents or adults were considered. A total of 1960 articles were retrieved from the databases, of which five studies were included in the qualitative synthesis. Two of these studies evaluated the drug atomoxetine, another study evaluated desipramine, and the remaining two studies evaluated methylphenidate, with fluvoxamine being associated with methylphenidate in one of the trials. Owing to the high heterogeneity among studies, it was not possible to combine data for meta-analyses. Although only few studies have been evaluated in this systematic review, the results point to a more significant benefit of atomoxetine. This is probably because this drug was studied in a wider age range and evaluated by more specific scales for both disorders. To further strengthen this evidence, randomized, controlled and multicenter clinical trials with larger sample sizes should be conducted.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/140873